These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 20384344)

  • 1. Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice.
    Ishikawa M; Shinei R; Yokoyama F; Yamauchi M; Oyama M; Okuma K; Nagayama T; Kato K; Kakui N; Sato Y
    J Med Chem; 2010 May; 53(9):3840-4. PubMed ID: 20384344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-substituted aryl(thio)ethers as potent partial agonists (or antagonists) for the histamine H3 receptor lacking a nitrogen atom in the side chain.
    Pelloux-Léon N; Fkyerat A; Piripitsi A; Tertiuk W; Schunack W; Stark H; Garbarg M; Ligneau X; Arrang JM; Schwartz JC; Ganellin CR
    J Med Chem; 2004 Jun; 47(12):3264-74. PubMed ID: 15163206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.
    Ishikawa M; Watanabe T; Kudo T; Yokoyama F; Yamauchi M; Kato K; Kakui N; Sato Y
    J Med Chem; 2010 Sep; 53(17):6445-56. PubMed ID: 20690643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives.
    Gbahou F; Vincent L; Humbert-Claude M; Tardivel-Lacombe J; Chabret C; Arrang JM
    Br J Pharmacol; 2006 Apr; 147(7):744-54. PubMed ID: 16432504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
    Menghin S; Pertz HH; Kramer K; Seifert R; Schunack W; Elz S
    J Med Chem; 2003 Dec; 46(25):5458-70. PubMed ID: 14640554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
    Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
    J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the binding site of the histamine H3 receptor. 1. Various approaches to the synthesis of 2-(1H-imidazol-4-yl)cyclopropylamine and histaminergic activity of (1R,2R)- and (1S,2S)-2-(1H-imidazol-4-yl)-cyclopropylamine.
    De Esch IJ; Vollinga RC; Goubitz K; Schenk H; Appelberg U; Hacksell U; Lemstra S; Zuiderveld OP; Hoffmann M; Leurs R; Menge WM; Timmerman H
    J Med Chem; 1999 Apr; 42(7):1115-22. PubMed ID: 10197956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-benzyl-1H-imidazoles with oxazoline termini as histamine H3 receptor agonists.
    Wijtmans M; Celanire S; Snip E; Gillard MR; Gelens E; Collart PP; Venhuis BJ; Christophe B; Hulscher S; van der Goot H; Lebon F; Timmerman H; Bakker RA; Lallemand BI; Leurs R; Talaga PE; de Esch IJ
    J Med Chem; 2008 May; 51(10):2944-53. PubMed ID: 18433114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and structure-activity relationships of N-aryl-piperidine derivatives as potent (partial) agonists for human histamine H3 receptor.
    Ishikawa M; Furuuchi T; Yamauchi M; Yokoyama F; Kakui N; Sato Y
    Bioorg Med Chem; 2010 Jul; 18(14):5441-8. PubMed ID: 20541426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inverse agonist histamine H3 receptor PET tracers labelled with carbon-11 or fluorine-18.
    Hamill TG; Sato N; Jitsuoka M; Tokita S; Sanabria S; Eng W; Ryan C; Krause S; Takenaga N; Patel S; Zeng Z; Williams D; Sur C; Hargreaves R; Burns HD
    Synapse; 2009 Dec; 63(12):1122-32. PubMed ID: 19670309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
    Kitbunnadaj R; Zuiderveld OP; De Esch IJ; Vollinga RC; Bakker R; Lutz M; Spek AL; Cavoy E; Deltent MF; Menge WM; Timmerman H; Leurs R
    J Med Chem; 2003 Dec; 46(25):5445-57. PubMed ID: 14640553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and functional characterization of imbutamine analogs as histamine H3 and H4 receptor ligands.
    Geyer R; Kaske M; Baumeister P; Buschauer A
    Arch Pharm (Weinheim); 2014 Feb; 347(2):77-88. PubMed ID: 24493592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
    Kazuta Y; Hirano K; Natsume K; Yamada S; Kimura R; Matsumoto S; Furuichi K; Matsuda A; Shuto S
    J Med Chem; 2003 May; 46(10):1980-8. PubMed ID: 12723960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).
    McLeod RL; Rizzo CA; West RE; Aslanian R; McCormick K; Bryant M; Hsieh Y; Korfmacher W; Mingo GG; Varty L; Williams SM; Shih NY; Egan RW; Hey JA
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1037-44. PubMed ID: 12649305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971.
    Hey JA; Aslanian R; Bolser DC; Chapman RW; Egan RW; Rizzo CA; Shih NY; Fernandez X; McLeod RL; West R; Kreutner W
    Arzneimittelforschung; 1998 Sep; 48(9):881-8. PubMed ID: 9793613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the binding distribution of agonist and antagonist ligands for histamine H3 receptors in pig brain by quantitative autoradiography.
    Mezzomo K; Cumming P; Minuzzi L
    Eur J Pharmacol; 2007 Jun; 564(1-3):75-9. PubMed ID: 17350614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structural and pharmacological properties of cyclopropane-based conformationally restricted analogs of 4-methylhistamine as histamine H3/H4 receptor ligands.
    Kobayashi T; Watanabe M; Yoshida A; Yamada S; Ito M; Abe H; Ito Y; Arisawa M; Shuto S
    Bioorg Med Chem; 2010 Feb; 18(3):1076-82. PubMed ID: 20045649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclopropane-based stereochemical diversity-oriented conformational restriction strategy: histamine H3 and/or H4 receptor ligands with the 2,3-methanobutane backbone.
    Watanabe M; Kobayashi T; Hirokawa T; Yoshida A; Ito Y; Yamada S; Orimoto N; Yamasaki Y; Arisawa M; Shuto S
    Org Biomol Chem; 2012 Jan; 10(4):736-45. PubMed ID: 22120611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig.
    McLeod RL; Aslanian R; del Prado M; Duffy R; Egan RW; Kreutner W; McQuade R; Hey JA
    J Pharmacol Exp Ther; 1998 Oct; 287(1):43-50. PubMed ID: 9765320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the histamine system in nefopam-induced antinociception in mice.
    Girard P; Pansart Y; Coppé MC; Verniers D; Gillardin JM
    Eur J Pharmacol; 2004 Oct; 503(1-3):63-9. PubMed ID: 15496297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.